Suppr超能文献

大鼠体内14C-丙戊酸钠和14C-丙戊酸特戊酰氧甲酯重复给药研究。大鼠重复口服14C-丙戊酸钠盐和14C-丙戊酸特戊酰氧甲酯后的药代动力学研究。

14C-NaVP and 14C-PEV repeated dose study in rat. Pharmacokinetic study in rats after repeated oral administrations of 14C-valproic acid sodium salt and 14C-valproic acid pivaloyl oxymethyl ester.

作者信息

Bertolino M, Acerbi D, Canali S, Giachetti C, Poli G, Ventura P, Zanolo G

机构信息

Istituto di ricerche Biomediche A. Marxer, RBM S.p.A., Colleretto Giacosa (TO), Italy.

出版信息

Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):223-9. doi: 10.1007/BF03189344.

Abstract

The absorption, excretion and tissue distribution of radioactivity after repeated oral equimolar doses of 14C-valproic acid sodium salt (NaVP) or 14C-valproic acid pivaloyl oxymethyl ester (PEV) was investigated in male rats treated once a day for 14 consecutive days. The 14th day plasma time-course of radioactivity after PEV administrations was characterised by a slow absorption rate with a delayed peak (tmax 2 h, Cmax 7.52 +/- 1.35 microg eq./ml), followed by a plateau lasting up to 8 h. After NaVP treatment, the main peak of radioactivity was observed 0.5 h after administration (Cmax 8.30 +/- 1.26 microg eq./ml) followed by a secondary peak due to biliary enterohepatic recycling. Starting from 4 h onwards, radioactivity levels after PEV treatment were higher than those after NaVP (AUCtau = 113.3 h.microg eq./ml after PEV vs 71.9 h.microg eq./ml after NaVP), but concentrations declined with similar terminal half-lives (52.8 h for PEV and 49.7 h for NaVP). Radioactivity recovered (0-432 h interval) in urine accounted for 79.3% (PEV) and 56.1% (NaVP) while, in faeces accounted for 9.1% (PEV) and 26.1% (NaVP) of total administered dose (14 days). The difference is attributable to a higher excretion of radioactivity in the bile for NaVP. The missing fraction in the total radioactivity balance is probably excreted in expired air, as observed in single dose studies. Radioactivity excreted in bile (0-8 h interval of the last 14th day) accounted for 5.1% (NaVP) and 0.23% (PEV) of the total administered dose (14 days). A possible explanation of this difference may be a different metabolism pattern for the two compounds. The negligible biliary excretion observed after PEV administration is probably due to an inhibition of the glucuronation of valproic acid (or other metabolites) caused by the pivalic acid. Due to the presence of the enterohepatic recycle, the radioactivity levels in intestine, 0.5 and 2 h after administration, were higher after NaVP administration. According to higher plasma levels, the radioactivity concentrations in liver, kidneys and some fat tissues were found to be slightly higher after PEV administration. At 120 h after the last treatment of both compounds, relevant tissue concentrations were observed in mesenteric lymphnodes, perirenal and brown fat. The tissue-plasma radio activity ratio appeared quite similar for the two compounds.

摘要

在连续14天每天给药一次的雄性大鼠中,研究了重复口服等摩尔剂量的14C-丙戊酸钠盐(NaVP)或14C-丙戊酸新戊酰氧甲酯(PEV)后放射性的吸收、排泄和组织分布情况。PEV给药后第14天血浆放射性的时程特征为吸收速率缓慢,峰值延迟出现(tmax为2小时,Cmax为7.52±1.35微克当量/毫升),随后是长达8小时的平台期。NaVP治疗后,给药后0.5小时观察到放射性主峰(Cmax为8.30±1.26微克当量/毫升),随后由于胆汁肠肝循环出现第二个峰。从4小时起,PEV治疗后的放射性水平高于NaVP治疗后的水平(PEV的AUCtau为113.3小时·微克当量/毫升,NaVP为71.9小时·微克当量/毫升),但浓度以相似的终末半衰期下降(PEV为52.8小时,NaVP为49.7小时)。尿液中回收的放射性(0 - 432小时时间段)占总给药剂量(14天)的79.3%(PEV)和56.1%(NaVP),而粪便中占9.1%(PEV)和26.1%(NaVP)。这种差异归因于NaVP在胆汁中放射性排泄较高。总放射性平衡中缺失的部分可能如单次剂量研究中所观察到的那样通过呼出气体排出。胆汁中排泄的放射性(最后第14天的0 - 8小时时间段)占总给药剂量(14天)的5.1%(NaVP)和0.23%(PEV)。这种差异的一个可能解释可能是两种化合物的代谢模式不同。PEV给药后观察到的可忽略不计的胆汁排泄可能是由于新戊酸对丙戊酸(或其他代谢物)葡萄糖醛酸化的抑制作用。由于存在肠肝循环,NaVP给药后给药后0.5小时和2小时肠道中的放射性水平较高。根据较高的血浆水平,PEV给药后肝脏、肾脏和一些脂肪组织中的放射性浓度略高。在两种化合物最后一次治疗后120小时,在肠系膜淋巴结、肾周和棕色脂肪中观察到相关的组织浓度。两种化合物的组织 - 血浆放射性比率似乎相当相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验